Abstract
We studied the expression of axin and β-catenin and their relation to clinicopathologic factors in 100 non–small cell lung cancers (NSCLCs) by immunohistochemical analysis. The mutation in exon 3 of the β-catenin gene was examined by polymerase chain reaction and direct sequencing. Preserved axin expression was significantly higher in well- and moderately differentiated NSCLC samples than in poorly differentiated ones. Reduced membranous expression of β-catenin was shown in 80 cases, whereas 26 cases had aberrant nuclear expression. Poor differentiation and lymph node metastasis were associated significantly with reduced β-catenin expression. Lower axin expression was related significantly to higher nuclear β-catenin expression. However, this study failed to detect any exon 3 mutation in the β-catenin gene in the 100 NSCLC samples. We conclude that reduced β-catenin and axin expression might predict poor differentiation in NSCLC. Reduced axin expression, but not mutation in exon 3, might be an important explanation for the abnormal β-catenin expression in NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have